ADC Therapeutics (ADCT) Free Cash Flow (2019 - 2023)
Historic Free Cash Flow for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to -$32.0 million.
- ADC Therapeutics' Free Cash Flow rose 7687.85% to -$32.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$121.9 million, marking a year-over-year increase of 1186.38%. This contributed to the annual value of -$124.7 million for FY2024, which is 229.69% down from last year.
- Latest data reveals that ADC Therapeutics reported Free Cash Flow of -$32.0 million as of Q4 2023, which was up 7687.85% from -$37.3 million recorded in Q3 2023.
- ADC Therapeutics' 5-year Free Cash Flow high stood at $2195.0 for Q3 2022, and its period low was -$138.2 million during Q4 2022.
- Its 5-year average for Free Cash Flow is -$20.9 million, with a median of -$58299.0 in 2021.
- In the last 5 years, ADC Therapeutics' Free Cash Flow skyrocketed by 10374.65% in 2022 and then plummeted by 170096560.36% in 2023.
- ADC Therapeutics' Free Cash Flow (Quarter) stood at -$33655.0 in 2019, then tumbled by 95285.53% to -$32.1 million in 2020, then surged by 99.82% to -$58588.0 in 2021, then crashed by 235829.38% to -$138.2 million in 2022, then skyrocketed by 76.88% to -$32.0 million in 2023.
- Its Free Cash Flow stands at -$32.0 million for Q4 2023, versus -$37.3 million for Q3 2023 and -$36.2 million for Q2 2023.